{
  "financial": {
    "monetary_amounts": [
      {
        "raw": "$5,033,301.46",
        "amount": 5033301.46,
        "context": "CASE NO. 23-12345\n\n    OBJECTION TO DISCLOSURE STATEMENT\n\n    The Debtor proposes to pay creditors $5,033,301.46 to satisfy claims totaling\n    $3,500,000.00, representing a premium of 1.44x over face value.",
        "position": 115
      },
      {
        "raw": "$3,500,000.00",
        "amount": 3500000.0,
        "context": "RE STATEMENT\n\n    The Debtor proposes to pay creditors $5,033,301.46 to satisfy claims totaling\n    $3,500,000.00, representing a premium of 1.44x over face value.\n\n    OWNERSHIP STRUCTURE:\n\n    Dr. Smith holds 51",
        "position": 160
      },
      {
        "raw": "$1,500,000.00",
        "amount": 1500000.0,
        "context": "\u00a7 363(b) to approve this settlement\n    without Court approval.\n\n    CLAIMS:\n\n    Secured claim #1: $1,500,000.00\n    Unsecured claim #2: $2,000,000.00\n    Priority claim #3: $500,000.00\n\n    The plan provides for",
        "position": 788
      },
      {
        "raw": "$2,000,000.00",
        "amount": 2000000.0,
        "context": "without Court approval.\n\n    CLAIMS:\n\n    Secured claim #1: $1,500,000.00\n    Unsecured claim #2: $2,000,000.00\n    Priority claim #3: $500,000.00\n\n    The plan provides for distribution of 100,000 shares (votin",
        "position": 826
      },
      {
        "raw": "$500,000.00",
        "amount": 500000.0,
        "context": ":\n\n    Secured claim #1: $1,500,000.00\n    Unsecured claim #2: $2,000,000.00\n    Priority claim #3: $500,000.00\n\n    The plan provides for distribution of 100,000 shares (voting) to Class A creditors\n    and 50,",
        "position": 863
      },
      {
        "raw": "$750,000.00",
        "amount": 750000.0,
        "context": "(non-voting) to Class B creditors.\n\n    INSIDER PAYMENT:\n\n    The plan also provides for payment of $750,000.00 to the CEO within 90 days of\n    the effective date, despite the CEO being a 20% shareholder.",
        "position": 1085
      }
    ],
    "percentages": [
      {
        "value": 51.0,
        "type": "voting_control",
        "entity": "\n\n    Dr",
        "context": ",301.46 to satisfy claims totaling\n    $3,500,000.00, representing a premium of 1.44x over face value.\n\n    OWNERSHIP STRUCTURE:\n\n    Dr. Smith holds 51% voting control but only 15% economic ownership of the\n    reorganized entity. This creates a control disparity of 36%.\n\n    Jane Doe owns 49% voting"
      },
      {
        "value": 15.0,
        "type": "voting_control",
        "entity": "\n\n    Dr",
        "context": "taling\n    $3,500,000.00, representing a premium of 1.44x over face value.\n\n    OWNERSHIP STRUCTURE:\n\n    Dr. Smith holds 51% voting control but only 15% economic ownership of the\n    reorganized entity. This creates a control disparity of 36%.\n\n    Jane Doe owns 49% voting shares and 85% economic owne"
      },
      {
        "value": 36.0,
        "type": "voting_control",
        "entity": "\n\n    Dr",
        "context": "STRUCTURE:\n\n    Dr. Smith holds 51% voting control but only 15% economic ownership of the\n    reorganized entity. This creates a control disparity of 36%.\n\n    Jane Doe owns 49% voting shares and 85% economic ownership.\n\n    LEGAL ISSUES:\n\n    The plan violates Purdue Pharma L.P. v. United States, 144"
      },
      {
        "value": 49.0,
        "type": "voting_control",
        "entity": " This",
        "context": "h holds 51% voting control but only 15% economic ownership of the\n    reorganized entity. This creates a control disparity of 36%.\n\n    Jane Doe owns 49% voting shares and 85% economic ownership.\n\n    LEGAL ISSUES:\n\n    The plan violates Purdue Pharma L.P. v. United States, 144 S. Ct. 2079 (2024),"
      },
      {
        "value": 85.0,
        "type": "voting_control",
        "entity": " This",
        "context": "trol but only 15% economic ownership of the\n    reorganized entity. This creates a control disparity of 36%.\n\n    Jane Doe owns 49% voting shares and 85% economic ownership.\n\n    LEGAL ISSUES:\n\n    The plan violates Purdue Pharma L.P. v. United States, 144 S. Ct. 2079 (2024),\n    which prohibits non-co"
      }
    ],
    "shares": [
      {
        "count": 100000,
        "type": "non-voting",
        "owner": "\n    Priority",
        "context": "aim #2: $2,000,000.00\n    Priority claim #3: $500,000.00\n\n    The plan provides for distribution of 100,000 shares (voting) to Class A creditors\n    and 50,000 shares (non-voting) to Class B creditors.\n\n    INSIDER PAYMENT"
      },
      {
        "count": 50000,
        "type": "non-voting",
        "owner": "\n\n    The",
        "context": ".00\n\n    The plan provides for distribution of 100,000 shares (voting) to Class A creditors\n    and 50,000 shares (non-voting) to Class B creditors.\n\n    INSIDER PAYMENT:\n\n    The plan also provides for payment of $750,000.00"
      }
    ],
    "claims": [
      {
        "amount": 3500000.0,
        "type": "general",
        "context": "claims totaling\n    $3,500,000.00"
      },
      {
        "amount": 1500000.0,
        "type": "secured",
        "context": "CLAIMS:\n\n    Secured claim #1: $1,500,000.00"
      },
      {
        "amount": 2000000.0,
        "type": "secured",
        "context": "Unsecured claim #2: $2,000,000.00"
      },
      {
        "amount": 500000.0,
        "type": "general",
        "context": "claim #3: $500,000.00"
      }
    ],
    "settlements": [
      {
        "payment_amount": 5033301.46,
        "original_amount": 3500000.0,
        "premium_multiple": 1.44,
        "context": "proposes to pay creditors $5,033,301.46 to satisfy claims totaling\n    $3,500,000.00"
      }
    ],
    "extraction_metadata": {
      "extracted_at": "2025-10-26T22:20:55.954410",
      "total_monetary_amounts": 6,
      "total_percentages": 5,
      "total_shares": 2,
      "total_claims": 4,
      "total_settlements": 1
    }
  },
  "ownership": {
    "voting_control": {
      "Smith": 51.0,
      "Jane Doe": 49.0
    },
    "economic_ownership": {},
    "control_disparities": []
  },
  "legal": {
    "case_citations": [],
    "statutory_references": [
      {
        "title": "11",
        "section": "363(b)",
        "citation": "11 U.S.C. \u00a7 363(b)"
      }
    ],
    "precedent_violations": [
      {
        "case": "The plan violates Purdue Pharma L.P. v. United States,",
        "citation": "The plan violates Purdue Pharma L.P. v. United States, 144 S. Ct. 2079 (2024)",
        "violation_type": "non-consensual_third_party_release",
        "context": "ontrol but only 15% economic ownership of the\n    reorganized entity. This creates a control disparity of 36%.\n\n    Jane Doe owns 49% voting shares and 85% economic ownership.\n\n    LEGAL ISSUES:\n\n    The plan violates Purdue Pharma L.P. v. United States, 144 S. Ct. 2079 (2024),\n    which prohibits non-consensual third-party releases in bankruptcy cases.\n\n    The Trustee lacks authority under 11 U.S.C. \u00a7 363(b) to approve this settlement\n    without Court approval.\n\n    CLA"
      }
    ],
    "authority_limitations": [
      {
        "limitation": "Trustee lacks authority",
        "context": "es Purdue Pharma L.P. v. United States, 144 S. Ct. 2079 (2024),\n    which prohibits non-consensual third-party releases in bankruptcy cases.\n\n    The Trustee lacks authority under 11 U.S.C. \u00a7 363(b) to approve this settlement\n    without Court approval.\n\n    CLAIMS:\n\n    Secured claim #1: $1,500,000.00\n    Unsecured claim"
      }
    ]
  },
  "metrics": {
    "settlement_inequities": [],
    "preferential_treatments": [],
    "suspicious_payments": [],
    "recovery_analysis": {
      "total_claims": 7500000.0,
      "total_payments": 5033301.46,
      "overall_recovery_rate": 0.671,
      "expected_bankruptcy_recovery": 0.3,
      "excess_recovery": 0.3711068613333333,
      "suspicious": false
    },
    "overall_statistics": {
      "total_settlements": 1,
      "preferential_treatments_found": 0,
      "settlement_inequities_found": 0,
      "suspicious_payments_found": 0,
      "highest_premium": 1.44,
      "average_premium": 1.44,
      "fraud_indicators": 0
    }
  },
  "creditor_recovery": {
    "by_class": {
      "general": {
        "total_claims": 4000000.0,
        "claim_count": 2,
        "estimated_recovery": 2684427.445333333,
        "recovery_rate": 0.671,
        "expected_rate": 0.25
      },
      "secured": {
        "total_claims": 3500000.0,
        "claim_count": 2,
        "estimated_recovery": 2348874.0146666667,
        "recovery_rate": 0.671,
        "expected_rate": 0.8
      }
    },
    "inequities": [
      {
        "creditor_class": "general",
        "actual_rate": 0.6711068613333333,
        "expected_rate": 0.25,
        "difference": 0.4211068613333333,
        "favored": true
      }
    ]
  },
  "fraudulent_conveyances": [
    {
      "amount": 3500000.0,
      "red_flags": [
        "large_payment",
        null,
        null,
        "controlled_entity"
      ],
      "context": "RE STATEMENT\n\n    The Debtor proposes to pay creditors $5,033,301.46 to satisfy claims totaling\n    $3,500,000.00, representing a premium of 1.44x over face value.\n\n    OWNERSHIP STRUCTURE:\n\n    Dr. S",
      "risk_level": "HIGH"
    },
    {
      "amount": 750000.0,
      "red_flags": [
        "large_payment",
        "insider_payment",
        "suspicious_timing",
        null
      ],
      "context": "(non-voting) to Class B creditors.\n\n    INSIDER PAYMENT:\n\n    The plan also provides for payment of $750,000.00 to the CEO within 90 days of\n    the effective date, despite the CEO being a 20% shareho",
      "risk_level": "HIGH"
    }
  ],
  "alerts": [
    {
      "level": "CRITICAL",
      "type": "LEGAL_VIOLATION",
      "message": "Violates The plan violates Purdue Pharma L.P. v. United States, - non-consensual_third_party_release"
    },
    {
      "level": "CRITICAL",
      "type": "FRAUDULENT_CONVEYANCE",
      "message": "Suspicious $3,500,000.00 transfer to insider/controlled entity"
    },
    {
      "level": "CRITICAL",
      "type": "FRAUDULENT_CONVEYANCE",
      "message": "Suspicious $750,000.00 transfer to insider/controlled entity"
    }
  ],
  "summary": {
    "Financial Data": {
      "Monetary Amounts": 6,
      "Claims": 4,
      "Settlements": 1,
      "Percentages": 5
    },
    "Ownership Structure": {
      "Voting Control Entities": 2,
      "Control Disparities": 0
    },
    "Legal Issues": {
      "Case Citations": 0,
      "Precedent Violations": 1,
      "Statutory References": 1
    },
    "Risk Assessment": {
      "Preferential Treatments": 0,
      "Fraudulent Conveyances": 2,
      "Total Fraud Indicators": 0
    }
  }
}